162 related articles for article (PubMed ID: 38170382)
21. Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.
Shi XY; Ding W; Li TQ; Zhang YX; Zhao SC
Med Sci Monit; 2017 Dec; 23():5793-5802. PubMed ID: 29211704
[TBL] [Abstract][Full Text] [Related]
22. N6-methyadenosine modified SUV39H2 regulates homologous recombination through epigenetic repression of DUSP6 in gastric cancer.
Yang J; Xu P; Chen Z; Zhang X; Xia Y; Fang L; Xie L; Li B; Xu Z
Cancer Lett; 2023 Apr; 558():216092. PubMed ID: 36806557
[TBL] [Abstract][Full Text] [Related]
23. CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway.
Ji J; Shen T; Li Y; Liu Y; Shang Z; Niu Y
Oncol Rep; 2021 Mar; 45(3):921-932. PubMed ID: 33650660
[TBL] [Abstract][Full Text] [Related]
24. RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis.
Bai Y; Yang Y; Yan Y; Zhong J; Blee AM; Pan Y; Ma T; Karnes RJ; Jimenez R; Xu W; Huang H
Theranostics; 2019; 9(12):3459-3475. PubMed ID: 31281490
[No Abstract] [Full Text] [Related]
25. miR-92a promotes proliferation and inhibits apoptosis of prostate cancer cells through the PTEN/Akt signaling pathway.
Yanshen Z; Lifen Y; Xilian W; Zhong D; Huihong M
Libyan J Med; 2021 Dec; 16(1):1971837. PubMed ID: 34431444
[TBL] [Abstract][Full Text] [Related]
26. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J
J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045
[TBL] [Abstract][Full Text] [Related]
27. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
[TBL] [Abstract][Full Text] [Related]
28. DOK3 promotes proliferation and inhibits apoptosis of prostate cancer via the NF-κB signaling pathway.
Jin K; Qiu S; Chen B; Zhang Z; Zhang C; Zhou X; Yang L; Ai J; Wei Q
Chin Med J (Engl); 2023 Feb; 136(4):423-432. PubMed ID: 36867541
[TBL] [Abstract][Full Text] [Related]
29. KAT5 and KAT6B are in positive regulation on cell proliferation of prostate cancer through PI3K-AKT signaling.
He W; Zhang MG; Wang XJ; Zhong S; Shao Y; Zhu Y; Shen ZJ
Int J Clin Exp Pathol; 2013; 6(12):2864-71. PubMed ID: 24294372
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells.
Ohigashi T; Mizuno R; Nakashima J; Marumo K; Murai M
Prostate; 2005 Jan; 62(1):61-8. PubMed ID: 15389810
[TBL] [Abstract][Full Text] [Related]
31. PCMT1 regulates the migration, invasion, and apoptosis of prostate cancer through modulating the PI3K/AKT/GSK-3β pathway.
Zhong J; Yuan C; Liu L; Du Y; Hui Y; Chen Z; Diao C; Yang R; Liu G; Liu X
Aging (Albany NY); 2023 Oct; 15(20):11654-11671. PubMed ID: 37899170
[TBL] [Abstract][Full Text] [Related]
32. Eya2 Is Overexpressed in Human Prostate Cancer and Regulates Docetaxel Sensitivity and Mitochondrial Membrane Potential through AKT/Bcl-2 Signaling.
Liu Z; Zhao L; Song Y
Biomed Res Int; 2019; 2019():3808432. PubMed ID: 31317026
[TBL] [Abstract][Full Text] [Related]
33. Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway.
Shukla S; Bhaskaran N; Babcook MA; Fu P; Maclennan GT; Gupta S
Carcinogenesis; 2014 Feb; 35(2):452-60. PubMed ID: 24067903
[TBL] [Abstract][Full Text] [Related]
34. LIM and SH3 protein 1 regulates cell growth and chemosensitivity of human glioblastoma via the PI3K/AKT pathway.
Zhong C; Chen Y; Tao B; Peng L; Peng T; Yang X; Xia X; Chen L
BMC Cancer; 2018 Jul; 18(1):722. PubMed ID: 29980193
[TBL] [Abstract][Full Text] [Related]
35. THBS4 silencing regulates the cancer stem cell-like properties in prostate cancer via blocking the PI3K/Akt pathway.
Hou Y; Li H; Huo W
Prostate; 2020 Jul; 80(10):753-763. PubMed ID: 32421868
[TBL] [Abstract][Full Text] [Related]
36. IMP3 accelerates the progression of prostate cancer through inhibiting PTEN expression in a SMURF1-dependent way.
Zhang X; Wang D; Liu B; Jin X; Wang X; Pan J; Tu W; Shao Y
J Exp Clin Cancer Res; 2020 Sep; 39(1):190. PubMed ID: 32938489
[TBL] [Abstract][Full Text] [Related]
37. Regulatory effects of antitumor agent matrine on FOXO and PI3K-AKT pathway in castration-resistant prostate cancer cells.
Li Q; Huang H; He Z; Sun Y; Tang Y; Shang X; Wang C
Sci China Life Sci; 2018 May; 61(5):550-558. PubMed ID: 29119376
[TBL] [Abstract][Full Text] [Related]
38. GPCR48/LGR4 promotes tumorigenesis of prostate cancer via PI3K/Akt signaling pathway.
Liang F; Yue J; Wang J; Zhang L; Fan R; Zhang H; Zhang Q
Med Oncol; 2015 Mar; 32(3):49. PubMed ID: 25636507
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of MicroRNA miR-101-3p on prostate cancer progression by regulating Cullin 4B (CUL4B) and PI3K/AKT/mTOR signaling pathways.
Gu Z; You Z; Yang Y; Ding R; Wang M; Pu J; Chen J
Bioengineered; 2021 Dec; 12(1):4719-4735. PubMed ID: 34338146
[TBL] [Abstract][Full Text] [Related]
40. Knockdown of GSG2 inhibits prostate cancer progression in vitro and in vivo.
Yu F; Lin Y; Xu X; Liu W; Tang D; Zhou X; Wang G; Zheng Y; Xie A
Int J Oncol; 2020 Jul; 57(1):139-150. PubMed ID: 32319597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
